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Abstract   
     Nanocomposite membranes based on thermosensitive, poly(N-isopropylacrylamide)-based nanogels 
and magnetite nanoparticles have been designed to achieve “on-demand” drug delivery upon the 
application of an oscillating magnetic field.  On-off release of sodium fluorescein over multiple 
magnetic cycles has been successfully demonstrated using prototype membrane-based devices.  The 
total drug dose delivered was directly proportional to the duration of the “on” pulse.  The membranes 
were non-cytotoxic, biocompatible, and retained their switchable flux properties after 45 days of 
subcutaneous implantation. 
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Delivery devices that allow remote, repeatable, and reliable switching of drug flux could have a 
marked impact on the treatment of a variety of medical conditions.  An ideal device for on-demand drug 
delivery should safely contain a large quantity of drug, release little or no drug in the “off” state, be 
repeatedly switchable to the “on” state without mechanically disrupting the device, and be triggered non-
invasively to release a consistent dosage demanded by a patient (e.g. local pain relief) or prescribed by a 
doctor (e.g. localized chemotherapy).   
Despite the clear clinical need, few such drug delivery devices have been developed and none are 
available for clinical use.  Existing technologies are particularly limited by their inability to be 
effectively triggered in vivo in the absence of a local implanted heat source, their lack of reproducible 
release over multiple thermal cycles, their slow response times to stimuli, and/or their inability to 
dynamically adjust drug dosing according to patient needs.  Currently, no existing device overcomes all 
of these limitations.  For example, radio frequency-activated microchips containing drug-filled 
reservoirs can achieve rapid on-demand drug delivery1, 2 but deliver only fixed doses of drug and require 
implanted electronics.  Near-IR responsive nanoparticles consisting of mixtures of PNIPAM and gold-
gold sulfide nanoshells can release proteins on demand but deliver inconsistent doses upon multiple 
triggering cycles3.  Ferrofluid-loaded polymer sheets4, liposomes5, microspheres6, 7, microcapsules8, 9, 
and nanospheres10-12 can be activated remotely by magnetic induction but typically achieve either single 
burst release events or inconsistent dosing over multiple thermal cycles due to the use of mechanical 
disruption of the drug-polymer matrix as the flux triggering mechanism.  Hence, alternative technologies 
are needed.   
Hydrogels13-18, gel-based microparticles19 or nanoparticles20-23, and surface-grafted polymers24-36 
based on thermosensitive poly(N-isopropylacrylamide) (PNIPAM) have been frequently used in 
triggerable devices.  With heating, PNIPAM undergoes a reversible discontinuous phase transition in 
water, switching from hydrophilic to hydrophobic37.  In a PNIPAM-based hydrogel, this phase transition 
induces a deswelling response which typically reduces drug flux from the hydrogel.  Alternately, when 
PNIPAM is used to fill the pores of a membrane, the pores are opened upon heating as the entrapped 
polymer shrinks, increasing drug flux through the membrane28, 38.  Such membranes have been designed 
by grafting poly(N-isopropylacrylamide) to existing membrane networks5 or by entrapping PNIPAM 
microgels within a membrane matrix39.  However, existing PNIPAM-based devices would be 
permanently “on” at physiological temperature (37°C) since their transition temperatures are ~32°C.  
3 
 
Existing technologies would also require use of an implanted heating system for effective in vivo 
activation.    
 
     Figure 1.  Physicochemical membrane characterization: (a) Mass percentages of ferrofluid, nanogel, and ethyl 
cellulose in membrane as a function of etch time, by XPS; (b) XRD spectrum of ferrofluid-loaded membranes in comparison 
to a magnetite-only control; (c) Transmission electron micrographs of ferrofluid distribution and size within the composite 
membrane;  (2 µm size bar, left panel; 100nm size bar, right panel); (d)  Magnetization curves for composite membranes 
measured at 5K and 280K.   
 
Here, we developed a composite membrane based on multiple engineered smart nanoparticles which 
enabled rapid, repeatable, and tunable drug delivery upon the application of an external oscillating 
magnetic field.  The membrane consisted of ethylcellulose (the membrane support), superparamagnetic 
magnetite nanoparticles (the triggering entity), and thermosensitive poly(N-isopropylacrylamide) 
(PNIPAM)-based nanogels37 (the switching entity).  Membranes were prepared by co-evaporation so 
that the nanogel and magnetite nanoparticles were entrapped in ethylcellulose to form a presumably 
disordered network.  Surface-etching x-ray photoelectron spectroscopy (XPS) showed that the 
membranes had a relatively uniform composition within the bulk but relatively less iron (ferrofluid) near 
the membrane surface (Figure 1a).  The membrane nanogel composition determined by XPS (23% by 
dry weight) correlated well with the nanogel concentration in the pre-membrane suspension (25% by dry 
weight).   
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     Figure 2.  Stimulus-responsive membrane 
triggering in vitro:  (a) Temperature-triggering: 
comparison of nanogel particle size in suspension (blue 
data, right y-axis) and differential flux of sodium 
fluorescein through the nanogel-loaded membranes (red 
data, left y-axis) as a function of temperature; (b) 
Magnetic triggering:  temperature profile in the sample 
chamber and differential flux of sodium fluorescein out of 
membrane-capped devices as a function of time over four 
successive on/off cycles of the external magnetic field; (c) 
schema of the proposed mechanism of membrane function 
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X-ray diffraction analysis suggested that ferrofluid particles had a magnetite crystal structure and an 
average crystallite size of ~12 nm (Figure 1b).  Transmission electron microscopy of a membrane 
section (Figure 1c) confirmed the average ferrofluid particle size of 10-25 nm and suggested that local 
ferrofluid clusters sized between 0.1 - 3 μm were distributed throughout the membrane.  The magnetic 
material within the membranes had a magnetic saturation value of 96.5 emu/g(Fe3O4) at 280 K (Figure 
1d), similar to values previously reported for bulk magnetite (93-96 emu/g)40.  Furthermore, the 
measured coercive field of 346 ± 4 Oe at 5 K is consistent with that of previously reported ferrofluid 
particles of similar size41.  These results suggested that the ferrofluid particles consisted of a single 
magnetic domain (i.e. all iron was in magnetite form) and had the superparamagnetic properties and 
average particle size required for effective magnetic induction heating in an oscillating magnetic field42.   
To facilitate effective in vivo triggering, the nanogels were engineered to remain swollen (i.e. in the 
“off” state) at physiological temperature by copolymerizing N-isopropylacrylamide (NIPAM) with N-
isopropylmethacrylamide (NIPMAM) and acrylamide (AAm).  The methyl group of NIPMAM sterically 
inhibits the phase transition43 while AAm is more hydrophilic than NIPAM44, both shifting the phase 
transition to higher temperatures.  The ratio between the monomers was chosen to maximize the size 
change from the swollen to the collapsed state, in order to optimize membrane pore opening when 
triggered.   
The ability of the membrane constituents and the composite membrane to trigger at physiologically 
relevant temperatures was evaluated using both thermal and magnetic stimuli.  Nanogels in free 
suspension in PBS underwent a ~400 nm change in diameter upon heating from physiological 
temperature to 50°C (Figure 2a), with >90% of the total deswelling transition completed at 43°C.  
Thermal triggering of the nanogel-containing membrane was tested by placing it between two chambers 
of a glass flow cell submerged in a water bath and evaluating the flux of sodium fluorescein across the 
membrane (i.e. between the chambers) as a function of time and temperature.   A ~20-fold higher flux of 
sodium fluorescein occurred at temperatures exceeding the volume phase transition temperature (~40°C) 
of the nanogels (Figure 2a).  FT-IR analysis confirmed that this permeability enhancement coincided 
with a change in the hydrogen bonding within the membrane, consistent with the occurrence of a 
nanogel volume phase transition.  Furthermore, the fluorescein flux could be switched on and off over 
multiple thermal cycles with high reproducibility, suggesting that the nanogel phase transition inside the 
membrane pores was fully reversible.  
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Figure 3.  Biological testing of membranes: (a) Cell viability (relative to a cell-only control well) for differentiated 
myoblasts, fibroblasts, mesothelial cells, and macrophages in the presence of membrane components and membranes; (b-g) 
Tissue response to implanted nanogel- loaded membrane (25% nanogel, 27% ferrofluid) after 4 and 45 days of implantation: 
(b) top view, 4 days post-implantation; (c) histological section of membrane-tissue interface, 400x magnification; (d) 
histological section of capsule inflammatory response, 100x magnification; (e) top view, 45 days post-implantation; (f) 
histological section of membrane-tissue interface, 40x magnification; (g) histological section of capsule inflammatory 
response, 400x magnification.  
 
Magnetic triggering was evaluated in small-scale devices made by gluing two 1 cm diameter 
membrane disks to the ends of a 1 cm length of silicone tubing filled with a sodium fluorescein solution.  
The devices were mounted singly inside a semi-adiabatic flow cell in a solenoid coil, with constant 
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water flow through the flow cell to permit continuous sampling of fluorescein release.  Figure 2b shows 
the magnetic triggering of the composite membrane.  The magnetic nanoparticles embedded in the 
membrane heated inductively when subjected to an external oscillating magnetic field, heating 
previously attributed to power absorption and subsequent magnetic relaxation of single-domain 
nanoparticles45.  At the applied magnetic frequency and field amplitude, the water inside the semi-
adiabatic flow cell heated from 37°C to ~42°C over the course of ~10 minutes, at which point the 
temperature reached steady state.  Heat generated by magnetite induction heating was transferred to the 
adjacent thermosensitive nanogels, causing the nanogels to shrink and permit drug diffusion out of the 
device.  When the magnetic field was turned off, the device cooled, causing the nanogels to re-swell and 
refill the membrane pores.  As a result, the drug flux returned back to a near-zero value (Figure 2c).  As 
in the thermally-activated experiments, a 10-to-20-fold differential flux was observed between the “off” 
and “on” states.  Furthermore, multiple on-off cycles could be performed without significantly changing 
the permeability of the membrane in the “off” state.  This reproducibility suggests that magnetically-
triggered physical distortion of the device42 plays no significant role in accelerating drug release from 
the membrane-based devices.   
 
Cycle Duration of “on” cycle 
(minutes) 
Total mass released 
(mg) 
Rate of drug release 
(mg/min) 
1 35 0.43 0.012 
2 40 0.47 0.012 
3 57 0.69 0.012 
4 75 0.83 0.011 
 
Table 1. Total mass of sodium fluorescein release and rate of drug release during each magnetic cycle 
shown in Figure 2b 
The membrane-based devices also permitted precise control of the amount of drug released as a 
function of the duration of the magnetic pulse.  Table 1 shows the dose of fluorescein delivered for each 
of the four magnetically-activated cycles shown in Figure 2, calculated by integrating the area under the 
absorbance vs. time curve for each cycle.  The mass of compound released over each triggering cycle 
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varied directly with the duration of the magnetic pulse (R2 = 0.995), with the rate of drug release varying 
by less than 10% in each cycle.  Thus, drug release could be controlled by modulating both the 
frequency and duration of magnetic pulse.   
The devices turned “on” with only a 1-2 minute time lag after the solution temperature reached 40°C 
and turn “off” with a ~5-10 minute lag from the cooling temperature profile (Figure 2b).  This response 
rate was much more rapid than that seen with bulk, interpenetrating hydrogel networks, which can 
exhibit swelling kinetics on the order of hours46.   
 
 
Figure 4.  Comparison of thermally-triggered membrane flux of a freshly-prepared membrane to a membrane explanted 
from a Sprague-Dawley rat after 45 days of implantation.  
 
 
 
To evaluate potential applicability of the membranes for in vivo drug delivery, we first evaluated the 
cytotoxicity of the membranes to a broad range of cell types (differentiated myoblasts, fibroblasts, 
macrophages, fibroblasts, macrophages, and mesothelial cells).  Figure 3a shows the viability of cells in 
media exposed to a composite membrane or its components (an ethylcellulose film, a 5 mg/mL 
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copolymer nanogel suspension, and a nanogel-loaded membrane), expressed as a ratio to cell survival in 
media alone as measured by the MTT assay.  No significant decrease in cell viability was observed in 
any cell line upon exposure to the composite membrane or its individual components.   
    Biocompatibility of 1 cm diameter composite membrane disks was tested by subcutaneously 
implanting 1 cm diameter membrane disks in Sprague-Dawley rats.  Rats were sacrificed at 
predetermined intervals, at which point the membrane and surrounding tissues were removed and 
analyzed by histology.  Representative tissue responses at 4 and 45 days post-implantation are shown in 
Figures 3b-g.  After 4 days, the membrane was not significantly walled off from the surrounding tissues, 
with only minimal tissue adhering to the membrane (Figure 3b).  The gross appearance of the implant at 
4 days was bland with only mild erythema consistent with the recent implantation.  Microscopically, 
there was acute and early chronic inflammation around the implant, as would be expected at this time 
point (Figures 3c and 3d).  At 45 days, there was a thin translucent tissue capsule around the implant 
(easily separable from the membrane by gentle dissection) with no evidence of tissue damage (Figures 
3e and 3f).  The implants were grossly intact at both time points.  The sections showed a mature fibrous 
capsule with macrophages and occasional foreign body giant cells at the material-tissue interface (Figure 
3g).  Occasional macrophages containing implant material were present in the tissue capsule, along with 
some residual free membrane material (Figure 3g).  There was no apparent amplification of an 
inflammatory response and no evidence of ongoing acute inflammation. 
     To assess whether membranes retained their inducible drug-releasing properties in vivo, a membrane 
was excised after 45 days of subcutaneous implantation, the thin tissue capsule was removed, and the 
thermally-triggered fluorescein flux was measured using a glass flow cell apparatus.  The flux response 
of the excised membrane was compared to that of a fresh, non-implanted membrane with the same 
composition, as shown in Figure 4.  No significant difference was observed in the flux differential 
between the “on” and “off” states or the absolute magnitude of fluorescein flux across the membrane 
before or after implantation.  This result suggests that protein adsorption or biofilm formation in vivo 
does not significantly impact the functionality of the membrane.  
The composite nanogel-ferrofluid membrane described here meets the important criteria for “on-
demand” drug delivery devices.  It can undergo a sharp, discontinuous volume phase transition at ≥40°C 
and so can be switched from the “off” state at normal physiological temperature to the “on” state at a 
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temperature where it would not typically be triggered by fever, local inflammation, etc.  The membrane 
could be switched on and off rapidly by the application and removal of an external oscillating magnetic 
field.  Thus, on-demand drug delivery could be triggered non-invasively without implanted electronics.  
Furthermore, the membrane remained stable during multiple magnetic triggering cycles and over 
extended in vivo implantation, making reproducible, multi-cycle drug delivery possible.  In each case, 
the functionality of the membrane was directly attributable to the nanoparticle properties; specifically, 
the rapid swelling kinetics and engineered phase transition behavior of the nanogel and the surface 
chemistry and optimized size of the magnetite nanoparticles for magnetic induction heating enabled the 
rapid, repeatable, and tunable drug release properties observed under physiological conditions. 
Composite membrane-based drug delivery devices have the potential to greatly increase the 
flexibility of pharmacotherapy and improve the quality of patients’ lives by providing repeated, long-
term, on-demand drug delivery for a variety of medical applications, including the treatment of pain 
(local or systemic anesthetic delivery), local chemotherapy, and insulin delivery.  Modulation of the 
magnetic field could allow for fine-tuning of the rate of drug release, in addition to the frequency and 
duration of treatments.  Additionally, the ability of the membranes to remotely and reversibly control 
chemical permeation may be applied in the design of triggered bioseparation modules, selective 
chemosensors, or externally activated microreactors.  
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